EXHIBIT 99.03
| | Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | | |
| | | | |
| | Press Release | | |
FIRST QUARTER 2007 RESULTS DATE NOTIFICATION
25 April 2007
Basingstoke, UK and Philadelphia, US – April 17, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will announce first quarter 2007 earnings on Wednesday 25 April 2007.
| Results press release will be issued at: | 12:00 BST / 07:00 EDT |
| Investor conference call time: | 14:00 BST / 09:00 EDT |
Live conference call for investors:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 BST/9:00 EDT.
Please RSVP ssalah@shire.com (T: +44 (0)1256 894 160) for this conference call.
The details of the live conference call are as follows:
| UK dial in | 0800 953 0936 |
| US dial in | 1866 224 2972 |
| International dial in | +44 (0) 1452 568 061 |
| Password/Conf ID | 5717753# |
Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks. Details are as follows:
| UK dial in | 0800 953 1533 / 0845 245 5205 |
| US dial in | 1866 247 4222 |
| International dial in | +44 (0) 1452 55 00 00 |
| Pin code | 5717753# |
| Webcast replay | www.shire.com, in the investors section |
For further information please contact:
Investor Relations | Souheil Salah (Rest of the World) | +44 1256 894 160 |
| | Heidi Wunder (North America) | +1 484 595 8970 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com
Registered in England 2883758 Registered Office as above
